Thanks boom, #FountainOfKnowledge, as always much appreciated. Is one of the directors of the imm a specialist in Sjogren's syndrome, I'm sure I've read that somewhere along the line. All seems to tie together nicely.
Whether or not the patent raises sp is immaterial to me. It certainly won't raise it enough to tempt me to sell any of my holding to derisk slightly. Here's hoping for a very good December. Good luck all, the next six months should be very interesting indeed
I believe there are a couple of new patent applications currently pending.
1) MODIFIED PEPTIDES AND THEIR USE FOR TREATING AUTOIMMUNE DISEASES
Listed under claim 6:- the family of connective tissue diseases (non specific systemic organ diseases), such as systemic lupus erythematosus (SLE), rheumatoid arthritis, mixed connective tissue disease, Sjogren's syndrome, or chronic juvenile arthritis; and/or organ-specific autoimmune pathologies, such as multiple sclerosis, insulin-dependent… Read More
First primary data may 2018, also FDA fast track approved.
Our first primary data is June 2017 (on proviso that we recruit for December) with 30 clinics recruiting 200, in fairness I think it would be more like 29 recruiting 180 factoring Mauritius. Equating to just over 6 per… Read More
Lostinfrance, the company have set key targets so I would understand the frustration in recruitment delays. However, having been a long term for some years I do not understand 'your god forbid' statement. The priority here in respect of Lupuzor is a successful trial, not a successful recruitment drive. Investing some patience after investing your hard earned cash will provide you a handsome return.
It's one and the same thing. As they cannot be recruited unless they have passed there criteria and screening test, as per the rns about Mauritius, therefore once the final patient is confirmed, there would be no reason to delay the dosing of said patient. I doubt that there would be an Rns to confirm 200 and then another to confirm the last is being dosed. Interestingly, the first patients dosed are close to finishing the trial (February 2017) Clearly that indicates no serious adverse affects… Read More
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.